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Tetranuclear chiral Cu(II)-Schiff-base complexes S-1 and R-1, were synthesised using enantiomerically pure
(S)-(H2vanPheol) and (R)-(H2vanPheol) ligands respectively in the ratio of 1 : 1 of Cu(NO3)2 to (S/R)-
(H2vanPheol) in MeOH at room temperature. A pair of polynuclear chiral Cu(II)-cluster complexes were
characterized using single-crystal X-ray diffraction, elemental analysis, infrared and CD spectroscopy.
The results revealed the importance of these chiral ligands encouraging the arrangement of copper
metal in non-centrosymmetric polar packing. The potential of the novel [Cu4(S/R-vanPheol)2(S/R-
HvanPheol)2(CH3OH)2](NO3)2 complexes as biologically active compounds was assessed in particular
regarding their anti-proliferative and anti-microbial properties.Introduction
Applications of metal-based drugs are of great interest, in
particular to nal alternatives to the Pt-based anticancer drug
cisplatin.1–4 The metals can have variable coordination number,
geometry, and redox states. To date, cisplatin is one of the most
widely used anticancer drugs although it shows signicant side-
effects such as nausea, bone-marrow production suppression,
and nephrotoxicity.1 Aiming to diminish the side effects and
resistance caused by cisplatin, the development of new thera-
peutic metal-based treatments are needed. Requirements for
the desired high efficiency therapeutic metal-based drugs are (i)
high inhibition of tumour angiogenesis with simultaneous
tumour cell death, (ii) diminishing the side effects and resis-
tance caused by cisplatin and (iii) biological activity in living
organisms.5 To this end, copper is a good candidate in
comparison to other transition metals because it acts as
a cofactor during the angiogenesis process6–8 where it enhances
the production of cytokinase, endothelial cell proliferation and
migration. The chelation of copper ions can also suppressInstitute of Technology, Engesserstrasse
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hemistry 2019angiogenesis and decrease tumour volume in animals.9–12
Recent studies reveal that the use of novel Schiff-base copper(II)-
based complexes can remarkably induce apoptosis, inhibit
proliferation, suppress migration, metastasis and angiogenesis
and thus inhibit the growth of cervical cancer.13–22 Schiff-base
ligand derivatives have been widely used in coordination
chemistry due to the advantages of their exible properties and
the easy manipulation of their coordination properties via the
variation of functional groups such as amine, alcohol, carbox-
ylate and sulfonate.23–26 Out of the small number of Cu(II)
complexes formed with pocket ligands only one of these
employs a chiral ligand and none contain Cu(II) coordination
clusters.
Herein we report the development of an ambient condition
synthesis with high yields where enantioselectivity provides an
atom efficient route to this system. The new enantiomerically
pure ligands were selected since they provide a tetradentate
coordination pocket which is ideally suited to accommodate
Cu(II)-ions to give the enantiopure complexes, [Cu4(S-
vanPheol)2(S-HvanPheol)2(CH3OH)2](NO3)2 (S-1) and [Cu4(R-
vanPheol)2(R-HvanPheol)2(CH3OH)2](NO3)2 (R-1) via self-
assembly in methanol under aerobic conditions. The single-
crystal X-ray diffraction, elemental analysis, infrared and
circular dichroism (CD) spectroscopy of Cu(II)-complexes and
biological activities have been investigated.Results and discussion
The synthesis of the Schiff-base ligands S/R-(H2vanPheol)
(Scheme 1) was performed by the condensation reaction
between 2-hydroxy-3-methoxybenzaldehyde (o-vanillin) and
enantiomerically pure S- or R-2-amino-3-phenyl-1-propanol
(phenylalaninol) under reux in absolute ethanol.27 TheRSC Adv., 2019, 9, 24087–24091 | 24087

































































































View Article Onlinecorresponding chiral Schiff-base ligand S-(H2vanPheol) or R-
(H2vanPheol) was reacted with Cu(NO3)2 in methanol. Green
block-like crystals of the complex S-1 or R-1with formula [Cu4(S/
R-vanPheol)2(S/R-HvanPheol)2(CH3OH)2](NO3)2 were obtained
aer 7 days.
Single-crystal X-ray analysis shows that S-1 and R-1 are iso-
structural and crystallize in the polar space group P21 with Z¼ 2
(Table 1).
Crystallization in a polar space group with Flack c parame-
ters of zero highlights the efficient transfer of chirality from the
chiral Schiff-base ligand to the coordination compound. Due to
the fact that S-1 and R-1 are a pair of enantiomers S-1 is selected



















Crystal size [mm3] 0.34  0.18  0.16
Radiation MoKa (l ¼ 0.71073)
2q range for data collection [] 3.232 to 53.462
Index ranges 13 # h # 13, 24 # k # 27,
Reections collected 29 165
Independent reections 14 517 [Rint ¼ 0.0493, Rsigma ¼
Data/restraints/parameters 14 517/29/940
Goodness-of-t on F2 0.938
Final R indices [I > 2s(I)] 0.0380
Final wR1 indices [all data] 0.0936
Largest diff. peak/hole [e Å3] 0.53/0.62
Flack parameter 0.010(7)
24088 | RSC Adv., 2019, 9, 24087–24091According to the X-ray crystallographic analyses, S-1 is
composed of an independent tetranuclear Cu(II) cluster
combining four Schiff-base ligands, which are oriented around
the cluster (Fig. 1). In each cluster, two ligands are doubly-
deprotonated, with their alkoxo oxygens (O6 or O12) forming
m3-bridges between copper centres, while the other two are
singly-deprotonated, with their alkoxy O–H groups (O3 or O9)
forming hydrogen bonds to nitrate counterions. In each tetra-
nuclear Cu(II) cluster compound, the core structure can be
regarding being based on a Cu4O4 cubane unit, in which the
Cu2+ centres are bridged by four deprotonated oxygens from
ligands. Although the two alkoxo oxygen (O6 and O12) form m3-
bridges, the two phenoxo oxygens O2 and O8 only form m2-
bridges. This results in a partial opening of the tetracubane
core, with the Cu3/O2 and Cu1/O8 edges now both over 3.2 Å.
The edges Cu1/Cu4 and Cu2/Cu3 are each further supported
by a hydrogen bond between the O–H of a methanol ligand and
a deprotonated but non-bridging phenoxo oxygen.
The charge balance is provided by two nitrate anions, which
form intermolecular hydrogen bonds with propanol groups of
the ligand. The Cu–O distances range from 1.904(4) to 2.423(4)
Å, whereas the Cu–N distances are between 1.930(5) and
1.948(5) Å. In addition, the O–Cu–O angles lie between
106.9(19) to 127.1(2) and the N–Cu–O angles between
82.31(19) and 172.8(2) (Table S1†). In R-1, the unidentate
ligand coordinating to Cu1 is not pure methanol, but a disor-
dered superposition of methanol (70%) and water (30%). This
disordered mixture inuences the position of the neighbouring

















0.58  0.23  0.18
MoKa (l ¼ 0.71073)
3.784 to 52.742
16 # l # 19 11 # h # 13, 26 # k # 26, 19 # l # 19
28 025
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Fig. 1 The structures of S-1 and R-1. The hydrogen atoms and nitrate
counterions are omitted for clarity. Hydrogen bonds are shown as
green dashed lines. Colour codes for the atoms: light blue (Cu), blue
(N), red (O) and black (C).
Fig. 2 CD spectra of 50 mM solution of S-1 and R-1 in MeOH.
Fig. 3 In vitro viability evaluation of A431 and HEK293 cells after
treatment with S-1 and R-1 for 48 h. The cellular metabolism was
determined as a measure of viability using a MTS assay. The
percentage of cell viability is expressed relative to vehicle-treated
control cells that were treated with the corresponding concentration

































































































View Article Onlinenitrate is pulled closer to the core structure than in methanol
case. The FTIR spectra in the region 4000–400 cm1 for
complexes S-1 and R-1 have been evaluated (Fig. S5†). The
comparison of these complexes with the free ligand revealed
that the strong and sharp bands in the region 1629–1630 cm1
can be assigned to the azomethine n(C]N) stretching frequency
of the coordinated ligands in S-1 and R-1. The shi of this band
towards a lower frequency compared to that of the free ligands
(1642–1605 cm1) indicates the coordination of the imine
nitrogen atom to the metal centre. The broad band around
3551–3167 cm1 is due to the n(OH) of the alcohol coordinated
to the metal centre. The other n(C–H), n(C]C) and n(C–O)
vibrations are found in the normal ranges for these types of
linkages.26 The maxima in the UV/vis absorption spectra of
complexes S-1 and R-1 at 376 nm (p–p*) and 660 nm (n–p*),
Cu(II) charge transfer transition, were found to be blue shied
from 419 nm in comparison to the free ligand. (Fig. S6†). No
uorescence emission was observed for either complex possibly
as a result of the quenching effect of unoccupied d orbitals of
the copper(II) through the nonradiative dissipation process.28This journal is © The Royal Society of Chemistry 2019Crystalline samples of S-1 and R-1 were prepared as 50 mM
solution in MeOH and their optical properties were evaluated
using circular dichroism (CD). S-1 and R-1 display opposite
Cotton effects over the measured range to give the expected
mirror image spectra. S-1 exhibits an intermediate positive peak
at 247 nm and strong negative peak at 271 nm plus a broad
negative peak at 371 nm. The mirror image complex R-1,
displays absorption peaks of the opposite sign in the same
wavelength range (Fig. 2).
The effect of S-1 and R-1 on the viability of living human cells
was investigated using the two cell lines A431 and HEK293
(Fig. 3). These in vitro studies revealed a comparable
concentration-dependent decrease in the number of metaboli-
cally active cells for both enantiomers. This suggests that the
observed effects of the complexes are independent of their
chirality. Interestingly, the human embryonic kidney cell line
HEK293 seems to be more sensitive to exposure to S-1 and R-1RSC Adv., 2019, 9, 24087–24091 | 24089
Table 2 IC50 values after incubation of A431 and HEK293 cells with S-
1 and R-1 for 48 h
IC50 [mM]
A431 HEK293
S-1 45.28  10.21 13.47  1.97
R-1 39.16  7.95 12.10  1.57

































































































View Article Onlinecompared to the more robust epidermoid human cancer cell
line A431 (Fig. 3). Consequently, the respective IC50 values for
HEK293 are less than half the values of A431 and are in the
same range as cisplatin (Table 2).
In addition to the viability assessment with regard to human
cells, the antibacterial activity of both compounds was evalu-
ated in the batch cultures, Gram-positive B. subtilis (Fig. 4) as
well as Gram-negative E. coli (Fig. S7†).Fig. 4 Cell densities measured at a wavelength of 600 nm (OD600)
during cultivation of Gram-positive B. subtilis in the presence of 10 mM
(circle), 50 mM (rhombus) or 100 mM (square) of S-1 (A) and R-1 (B),
respectively.
24090 | RSC Adv., 2019, 9, 24087–24091These analyses showed that both enantiomers possess
comparable growth inhibitory effects towards the Gram-positive
strain, but have no bactericidal activity against its Gram-
negative counterpart. Incubation of B. subtilis in the presence
of 50 or 100 mM of either S-1 or R-1 prevents their growth
entirely, whereas addition of 10 mM of both substances led only
to growth delay.
Conclusions
We have developed a high yield synthetic route to chiral Schiff-
base pocket ligands. A pair of chiral Schiff-base Cu(II)-clusters
have been successfully prepared under aerobic conditions and
these are the rst examples of Cu(II) coordination clusters
captured in chiral Schiff-base pocket ligands. Single-crystal X-
ray analysis shows that S-1 and R-1 are isostructural and crys-
tallize in the polar space group P21 with Z ¼ 2. The crystalliza-
tion in a polar space group highlights the efficient transfer of
chirality from the chiral Schiff-base ligand to the coordination
compound which exhibit the expected mirror image spectra for
the Cotton effect using CD spectroscopy. Both enantiomerically
pure Cu(II)-complexes exhibit anti-proliferative properties
against human cell lines and anti-microbial activity against
Gram-positive bacteria, although the observed effects of the
complexes are independent of their chirality. Additionally,
these Cu(II) chiral complexes will be further investigated as
catalysts for asymmetric reactions. In addition we plan to study
complexes formed with other M(II) ions.
Conflicts of interest
The authors declare no conict of interest.
Acknowledgements
We thank the DFG for funding through SFB/TRR 88 “3MET”,
Helmholtz POF STN, and Helmholtz Association (VH-VI-422)
and Dr Stephan Sinn for the CD measurement. We are
furthermore grateful to Utta Herzog for excellent technical
assistance.
References
1 S. Dasari and P. B. Tchounwou, Eur. J. Pharmacol., 2014, 740,
364–378.
2 Y. Ho, S. C. F. Au-Yeung and K. K. W. To,Med. Res. Rev., 2003,
23, 633–655.
3 N. Graf and S. J. Lippard, Adv. Drug Delivery Rev., 2012, 64,
993–1004.
4 K. Yoh, K. Kubota, H. Ohmatsu, K. Goto, S. Niho and Y. Ohe,
Anticancer Res., 2012, 32, 4131–4135.
5 N. P. E. Barry and P. J. Sadler, Chem. Commun., 2013, 49,
5106–5131.
6 G. F. Hu, J. Cell. Biochem., 1998, 69, 326–335.
7 C. K. Sen, S. Khanna, M. Venojarvi, P. Trikha, E. C. Ellison,
T. K. Hunt and S. Roy, Am. J. Physiol.: Heart Circ. Physiol.,

































































































View Article Online8 C. J. M. D. Griffith and J. P. Parker, Anti-Cancer Agents Med.
Chem., 2010, 10, 354–370.
9 C. Cox, T. N. Teknos, M. Barrios, G. J. Brewer, R. D. Dick and
S. D. Merajver, Laryngoscope, 2001, 111, 696–701.
10 J. Yoshii, H. Yoshiji, S. Kuriyama, Y. Ikenaka, R. Noguchi,
H. Okuda, H. Tsujinoue, T. Nakatani, H. Kishida,
D. Nakae, D. E. Gomez, M. S. De Lorenzo, A. M. Tejera and
H. Fukui, Int. J. Cancer, 2001, 94, 768–773.
11 Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema,
C. Bias, M. de Carvalho, E. A. Mesri, D. M. Robins,
R. D. Dick, G. J. Brewer and S. D. Merajver, Cancer Res.,
2002, 62, 4854–4859.
12 L. Finney, S. Vogt, T. Fukai and D. Glesne, Clin. Exp.
Pharmacol. Physiol., 2009, 36, 88–94.
13 X. Y. Qin, L. C. Yang, F. L. Le, Q. Q. Yu, D. D. Sun, Y. N. Liu
and J. Liu, Dalton Trans., 2013, 42, 14681–14684.
14 A. E. Stacy, D. Palanimuthu, P. V. Bernhardt,
D. S. Kalinowski, P. J. Jansson and D. R. Richardson, J.
Med. Chem., 2016, 59, 4965–4984.
15 X.-Y. Qin, Y.-N. Wang, X.-P. Yang, J.-J. Liang, J.-L. Liu and
Z.-H. Luo, Dalton Trans., 2017, 46, 16446–16454.
16 S. Zehra, T. Roisnel and F. Arjmand, ACS Omega, 2019, 4,
7691–7705.This journal is © The Royal Society of Chemistry 201917 P. Daneshmand, J. L. Jime, M. Aragon–alberti and
F. Schaper, Organometallics, 2018, 37, 1751–1759.
18 C. M. Rajesh and M. Ray, Dalton Trans., 2014, 43, 12952–
12960.
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